Date: 2014-04-07
Type of information: IPO
Company: Genomic Vision (France)
Investors:
Amount: €23 million
Funding type: IPO
Planned used: Genomic Vision is a molecular diagnostics company that develops and markets diagnostic tests and research tools based on analysing individual DNA molecules. To do so, it uses the “molecular combing” technology discovered by Aaron Bensimon, Chairman of the Executive Board and co-founder of Genomic Vision, who was working at the time at the Institut Pasteur’s Unité de Stabilité des Génomes unit in collaboration with a research team from Ecole Normale Supérieure. This technology detects quantitative and qualitative variations in the genome and establishes their role in a given pathology. The company focuses primarily on oncogenetics.
Others: * On April 7, 2014, Genomic Vision has announced it has raised €23 million through its IPO on Euronext Paris (compartment C). Given strong demand — a total €93.9 million — the company decided to fully exercise the extension option. The admission and issue price of Genomic Vision shares was set at €15.00, in the middle of the indicative price range. Altogether 1,533,332 shares were issued, raising a total of €23 million before any exercise of the over-allotment option. Based on a total 4,266,907 shares admitted to trading at €15 per share, Genomic Vision’s market capitalisation stands at €64 million.
Therapeutic area: Diagnostic - Cancer - Oncology
